John Sourbeer
Stock Analyst at UBS
(0.78)
# 3,965
Out of 5,006 analysts
39
Total ratings
36.84%
Success rate
-16.48%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $46.96 | +6.47% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $268.07 | +19.37% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $190.43 | +26.03% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $9.98 | +10.22% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $24.53 | -4.20% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $29.60 | +52.03% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.52 | +31.58% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $101.02 | +43.54% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $530.30 | -9.49% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $36.46 | +179.76% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $12.64 | +295.57% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $133.74 | -4.29% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $46.96
Upside: +6.47%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $268.07
Upside: +19.37%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $190.43
Upside: +26.03%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $9.98
Upside: +10.22%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $24.53
Upside: -4.20%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $29.60
Upside: +52.03%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.52
Upside: +31.58%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $101.02
Upside: +43.54%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $530.30
Upside: -9.49%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $36.46
Upside: +179.76%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $12.64
Upside: +295.57%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $133.74
Upside: -4.29%